Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Retinoic acid receptor

6

Retinoic acid receptor beta

6

Retinoic acid receptor gamma

6

Retinoid X receptor alpha

6

Retinoid X receptor gamma

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1971

6

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

AIDS-related Kaposi’s sarcoma

6

Acne vulgaris

6

Acute promyelocytic leukemia

6

severe recalcitrant nodular acne

6

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

6

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

6

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ligand Pharmaceuticals

6

Mester, B.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

8

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

EPA CompTox

8

FDA UNII

8

PUBCHEM

8

CHEBI

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

DERMATOLOGICALS

3

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTI-ACNE PREPARATIONS

2

ANTINEOPLASTIC AGENTS

2

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTI-ACNE PREPARATIONS FOR TOPICAL USE

2

OTHER ANTINEOPLASTIC AGENTS

2

ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

1

OTHER DERMATOLOGICAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other antineoplastic agents

2

Retinoids for topical use in acne

2

Agents for dermatitis, excluding corticosteroids

1

Other dermatologicals

1

Retinoids for treatment of acne

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

TRETINOIN

5688UTC01R

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

CYSTINE, D-

KX1RHN0Y0B

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cystine/glutamate transporter

Conditions:

DL-Cystine is a racemic mixture of the proteinogenic amino acids L-cystine and the non-proteinogenic D-cystine. Cystine is the oxidized dimer form of the amino acid cysteine. L-Cystine serves two biological functions, a site of redox reactions and a ...

mechanical linkage that allows proteins to retain their 3-dimensional structure. DL-cystine is used in the preparation of sulfur-containing dimeric and monomeric surfactants.

ALITRETINOIN

1UA8E65KDZ

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

TRETINOIN ZINC

7A9179CU3G

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

SODIUM RETINOATE

DD7YX785YA

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

ISOTRETINOIN ANISATIL

922SI67369

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

ISOTRETINOIN

EH28UP18IF

Export Data
Search for Structure

Status:

US Approved Rx (1997)

First approved in 1971

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Retinoic acid receptor

Retinoid X receptor alpha

Retinoic acid receptor gamma

Retinoid X receptor gamma

Retinoid X receptor alpha

Retinoic acid receptor beta

Conditions:

Acute promyelocytic leukemia

AIDS-related Kaposi’s sarcoma

severe recalcitrant nodular acne

Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid in...

dicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.

CYSTINE, DL-

06681CV9GH

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cystine/glutamate transporter

Conditions:

DL-Cystine is a racemic mixture of the proteinogenic amino acids L-cystine and the non-proteinogenic D-cystine. Cystine is the oxidized dimer form of the amino acid cysteine. L-Cystine serves two biological functions, a site of redox reactions and a ...

mechanical linkage that allows proteins to retain their 3-dimensional structure. DL-cystine is used in the preparation of sulfur-containing dimeric and monomeric surfactants.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1